Literature DB >> 31883651

The influence of CFTR complex alleles on precision therapy of cystic fibrosis.

Benoit Chevalier1, Alexandre Hinzpeter2.   

Abstract

CFTR is an extensively studied gene and multiple sequence variants have been identified, many of which still need to be defined as neutral or disease causing. Complex alleles are defined when at least two variants are identified on the same allele. Each pathogenic variant can affect distinct steps of the CFTR biogenesis. As CFTR modulators are being developed to alleviate specific defects, pathogenic variants need to be characterized to propose adequate treatments. Conversely, cis-variants can affect treatment response when defects are additive or if they alter the binding or efficacy of the modulator. Hence, complex alleles increase the complexity of CFTR variant classification and need to be assigned as neutral, disease causing or modulating treatment efficacy. This review was based on a symposium session presented at the 16th ECFS Basic Science Conference, Dubrovnik, Croatia, 27 to 30 March, 2019.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  CFTR; Cis-mutation; Complex alleles; Cystic fibrosis; Orkambi; Pathogenic variant; Splicing defects

Year:  2019        PMID: 31883651     DOI: 10.1016/j.jcf.2019.12.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

1.  Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis.

Authors:  Sean A Aspinall; Kelly A Mackintosh; Denise M Hill; Bethany Cope; Melitta A McNarry
Journal:  Int J Environ Res Public Health       Date:  2022-05-17       Impact factor: 4.614

2.  The era of CFTR modulators: improvements made and remaining challenges.

Authors:  Sara Cuevas-Ocaña; Onofrio Laselva; Julie Avolio; Raffaella Nenna
Journal:  Breathe (Sheff)       Date:  2020-06

3.  High frequency of complex CFTR alleles associated with c.1521_1523delCTT (F508del) in Russian cystic fibrosis patients.

Authors:  Nika V Petrova; Nataliya Y Kashirskaya; Tatyana A Vasilyeva; Natalia V Balinova; Andrey V Marakhonov; Elena I Kondratyeva; Elena K Zhekaite; Anna Y Voronkova; Sergey I Kutsev; Rena A Zinchenko
Journal:  BMC Genomics       Date:  2022-04-01       Impact factor: 3.969

4.  Things come in threes: A new complex allele and a novel deletion within the CFTR gene complicate an accurate diagnosis of cystic fibrosis.

Authors:  Ilaria Persico; Agnese Feresin; Michela Faleschini; Giorgia Fontana; Fabio Sirchia; Flavio Faletra; Martina La Bianca; Sarah Suergiu; Marcello Morgutti; Massimo Maschio; Adamo Pio D'Adamo; Karen S Raraigh; Anna Savoia; Roberta Bottega
Journal:  Mol Genet Genomic Med       Date:  2022-03-29       Impact factor: 2.473

Review 5.  Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges.

Authors:  Thierry Bienvenu; Maureen Lopez; Emmanuelle Girodon
Journal:  Genes (Basel)       Date:  2020-06-04       Impact factor: 4.096

6.  The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs.

Authors:  Elvira Sondo; Federico Cresta; Cristina Pastorino; Valeria Tomati; Valeria Capurro; Emanuela Pesce; Mariateresa Lena; Michele Iacomino; Ave Maria Baffico; Domenico Coviello; Tiziano Bandiera; Federico Zara; Luis J V Galietta; Renata Bocciardi; Carlo Castellani; Nicoletta Pedemonte
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.